Comparison Between Olympus EZ Shot 3Plus 19G & EZ Shot 2 19G in EUS-guided

Status Completed

Clinical Trial Summary

Endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) is a valid and recommended technique for tissue diagnosis of pancreatic masses. However, the diagnostic yield is with a sensitivity of 64%-95% and an accuracy of 78%-94% still very low. The EUS-FNB of pancreatic masses is usually performed with a 22-gauge biopsy needle. The small diameter of the needle is usually responsible for the low yield of tissue samples for histopathological examination. The 19-gauge needles help to overcome the limitations of a 22-gauge needle by acquiring a larger amount of cellular material. Thus, performing EUS-FNB with a 19-gauge needle can maximize tissue acquisition and sample adequacy, which is important for appropriate diagnosis. Contrariwise, the technical success rate for sample retrieval in patients with pancreatic head lesions is significantly lower using the 19-gauge compared to the 22-gauge needle. This is attributable to the technical difficulty to push the needle out of the endoscope in the duodenum. Since about 60% of pancreatic cancers are located in the head region, it is therefore particularly important to improve technical success in these cases. The new 19-gauge biopsy needle "Olympus EZ Shot3 Plus" is more flexible than common biopsy needles such as "EZ Shot2" and should therefore provide improved access to regions like pancreatic head. The aim of this multicenter prospective randomized crossover study is to compare those two needles during EUS-FNB of solid pancreatic masses.

Therefore this study will enroll 40 patients in five German centers with solid pancreatic masses and consecutive indication for EUS-FNB. Both needles will be used in each patient following a predetermined random order.

Primary endpoint is the correct histological diagnosis of the mass assessed by each needle. Technical failure is regarded as a negative histological diagnosis.

Secondary endpoints include a comparison of technical failure using each needle, histological quality, duration of procedure and rate of adverse events.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pancreatic Neoplasms

Clinical Trial Details

NCT number	NCT02909530
Study type	Interventional
Source	University of Ulm
Contact
Status	Completed
Phase	N/A
Start date	September 2016
Completion date	February 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04085055` - Fine Needle Biopsy of Solid Pancreatic Mass Lesions	N/A
Recruiting	`NCT01950572` - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated	`NCT00529113` - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer	Phase 1
Recruiting	`NCT05351983` - Patient-derived Organoids Drug Screen in Pancreatic Cancer	N/A
Recruiting	`NCT04809935` - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy	Phase 4
Recruiting	`NCT05481476` - Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT04652271` - International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
Active, not recruiting	`NCT02950064` - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations	Phase 1
Completed	`NCT03054987` - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction	N/A
Completed	`NCT02374411` - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients	N/A
Completed	`NCT01770405` - Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract	N/A
Terminated	`NCT01313416` - Gemcitabine and CT-011 for Resected Pancreatic Cancer	Phase 2
Terminated	`NCT01515046` - Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer	Phase 2
Enrolling by invitation	`NCT01465425` - Extracolonic Findings on Computed Tomography (CT) Colonography
Terminated	`NCT01434459` - Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin	Phase 1
Completed	`NCT00985777` - Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia	Phase 1
Completed	`NCT00385177` - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT00178763` - Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer	Phase 2
Completed	`NCT00136669` - Acupuncture For Pancreatic Cancer Pain	Phase 3
Completed	`NCT00196105` - Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms